Phase II Trial of BIBW 2992 in Patients With HER2-Positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy.
Phase of Trial: Phase II
Latest Information Update: 26 Dec 2013
At a glance
- Drugs Afatinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database record, EudraCT2007-004805-80).
- 20 Aug 2010 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 02 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.